Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Hikma Pharmaceuticals Plc delivers double digit revenue growth & increased profits in FY24

Hikma Pharmaceuticals reports strong 2024 results, with double-digit revenue growth, increased profits, and strategic acquisitions fueling optimism for 2025...

Convatec Group Plc reports broad-based, sustainable and profitable growth

Convatec Group Plc reports robust FY24 results with double-digit growth in EPS and cash flow, driven by strategic execution and expanded product offerings...

GSK Plc completes acquisition of IDRx, Inc.

GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor...

GSK Plc 5-in-1 meningococcal vaccine approved by FDA

GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates...

GSK Plc reports strong growth in Specialty Medicines and R&D progress

GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns...

GSK plc Depemokimab applications accepted for review in China and Japan

GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results...

GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe...

AstraZeneca Plc Datroway approved in the US for metastatic breast cancer

AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases...

GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment

GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates...

FDA accepts review of GSK Plc’s prefilled Shingrix syringe for vaccine approval

GSK's Shingrix aims for FDA-approved prefilled syringe to simplify shingles vaccination, enhancing convenience for healthcare providers...

GSK Plc’s ADC receives US FDA Breakthrough Therapy Designation

GSK's ADC GSK5764227 gains FDA Breakthrough Therapy status for treating relapsed or refractory osteosarcoma, addressing critical unmet medical needs...

GSK Plc’s Nucala approved in China as a treatment for CRSwNP

GSK's Nucala has been approved in China as an add-on treatment for CRSwNP, marking the first anti-IL-5 therapy for adults with this chronic condition...

AstraZeneca’s Tagrisso approved in the EU for patients with unresectable NSCLC

AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...

GSK Plc FIRST trial meetss primary endpoint in ovarian cancer

GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement...

GSK Plc receives US FDA Breakthrough Therapy Designation

GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development...

GSK Plc Nucala COPD submission accepted by FDA

GSK announces FDA review of Nucala for COPD treatment following successful MATINEE study data, aiming to be the first approved monthly biologic...

AstraZeneca Plc Imfinzi approved in the US for limited-stage SCLC

AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...

GSK plc RSV vaccine Arexvy approved in Japan

GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage...

AstraZeneca Plc expands US R&D and manufacturing footprint with $3.5b investment

AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...
Search

Funds

Health

Hikma Pharmaceuticals Plc delivers double digit revenue growth & increased profits in FY24

Hikma Pharmaceuticals reports strong 2024 results, with double-digit revenue growth, increased profits, and strategic acquisitions fueling optimism for 2025...

Convatec Group Plc reports broad-based, sustainable and profitable growth

Convatec Group Plc reports robust FY24 results with double-digit growth in EPS and cash flow, driven by strategic execution and expanded product offerings...

GSK Plc completes acquisition of IDRx, Inc.

GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor...

GSK Plc 5-in-1 meningococcal vaccine approved by FDA

GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates...

GSK Plc reports strong growth in Specialty Medicines and R&D progress

GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns...

GSK plc Depemokimab applications accepted for review in China and Japan

GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results...

GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe...

AstraZeneca Plc Datroway approved in the US for metastatic breast cancer

AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases...

GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment

GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates...

FDA accepts review of GSK Plc’s prefilled Shingrix syringe for vaccine approval

GSK's Shingrix aims for FDA-approved prefilled syringe to simplify shingles vaccination, enhancing convenience for healthcare providers...

GSK Plc’s ADC receives US FDA Breakthrough Therapy Designation

GSK's ADC GSK5764227 gains FDA Breakthrough Therapy status for treating relapsed or refractory osteosarcoma, addressing critical unmet medical needs...

GSK Plc’s Nucala approved in China as a treatment for CRSwNP

GSK's Nucala has been approved in China as an add-on treatment for CRSwNP, marking the first anti-IL-5 therapy for adults with this chronic condition...

AstraZeneca’s Tagrisso approved in the EU for patients with unresectable NSCLC

AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...

GSK Plc FIRST trial meetss primary endpoint in ovarian cancer

GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement...

GSK Plc receives US FDA Breakthrough Therapy Designation

GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development...

GSK Plc Nucala COPD submission accepted by FDA

GSK announces FDA review of Nucala for COPD treatment following successful MATINEE study data, aiming to be the first approved monthly biologic...

AstraZeneca Plc Imfinzi approved in the US for limited-stage SCLC

AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...

GSK plc RSV vaccine Arexvy approved in Japan

GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage...

AstraZeneca Plc expands US R&D and manufacturing footprint with $3.5b investment

AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...
Search

Funds

Health

FTSE 100

Funds